Analysis on Differential Gene Expression Data for Prediction of New Biological Features in Permanent Atrial Fibrillation

Feng Ou¹, Nini Rao¹*, Xudong Jiang², Mengyao Qian¹, Wei Feng¹, Lixue Yin³, Xu Chen³

¹School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China, ²School of Electrical and Electronic Engineering, Nanyang Technological University, Nanyang Link, Singapore, Singapore, ³Cardiovascular department, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China

Abstract

Permanent Atrial fibrillation (pmAF) has largely remained incurable since the existing information for explaining precise mechanisms underlying pmAF is not sufficient. Microarray analysis offers a broader and unbiased approach to identify and predict new biological features of pmAF. By considering the unbalanced sample numbers in most microarray data of case-control, we designed an asymmetric principal component analysis algorithm and applied it to re-analyze differential gene expression data of pmAF patients and control samples for predicting new biological features. Finally, we identified 51 differentially expressed genes using the proposed method, in which 42 differentially expressed genes are new findings compared with two related works on the same data and the existing studies. The enrichment analysis illustrated the reliability of identified differentially expressed genes. Moreover, we predicted three new pmAF-related signaling pathways using the identified differentially expressed genes via the KO-Based Annotation System. Our analysis and the existing studies supported that the predicted signaling pathways may promote the pmAF progression. The results above are worthy to do further experimental studies. This work provides some new insights into molecular features of pmAF. It has also the potentially important implications for improved understanding of the molecular mechanisms of pmAF.

Citation: Ou F, Rao N, Jiang X, Qian M, Feng W, et al. (2013) Analysis on Differential Gene Expression Data for Prediction of New Biological Features in Permanent Atrial Fibrillation. PLoS ONE 8(10): e76166. doi:10.1371/journal.pone.0076166

Editor: Ying Xu, University of Georgia, United States of America

Received March 12, 2013; Accepted August 21, 2013; Published October 18, 2013

Copyright: © 2013 Ou et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from National Natural Science Foundation (Grant No. 81171411) and Key Technology Research and Development Program of Sichuan Province (Grant No. 2011FZ0034). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: raonn@uestc.edu.cn

Introduction

Atrial fibrillation (AF) is an extremely common cardiac rhythm disorder in population [1,2]. The outstanding progresses have shown that AF pathophysiology involves electrical, structural and contractile remodeling, which is related to changes in cardiac gene expression.

Over the last decade, several studies have characterized the molecular basis of remodeling on a more global scale [3–7], in which Barth et al. [5] and Censi, et al. [6] respectively analyzed the same differential gene expression data with 10 permanent AF (pmAF) patients and 20 controls and found different biological features. In the atrial myocardium, Barth et al. [5] identified 1434 genes deregulated in pmAF. Besides, they found that most ventricular–predominant genes were upregulated in pmAF. They thought that dedifferentiation with adoption of a ventricular–like signature is a general feature of the fibrillating atrium. In the work of Censi, et al. [6], they applied the oblique principal component analysis (OPCA, a PCA–based method) to mine some new pmAF-related differentially expressed genes (DEGs) that were different from those in the work of Barth et al. [5] and found an attractor-like property of gene expression. Furthermore, Censi, et al. [7] analyzed the connection relationships among the identified DEGs. Their work showed that the connection relationships between AF and normal patient populations have great difference. However, any a quantitative analysis method for gene expression data has its limitations. For example, the PCA-based method might ignore some components that are, though statistically unimportant, biologically meaningful. The classical supervised approaches (such as SAM) were not able to well characterize different pathophysiological features of AF. Therefore, constant refinement is needed to evolve better methodologies to find more new biological features associated with AF for improved understanding of pathophysiological mechanisms of AF.

In this work, we designed an asymmetric principal component analysis (APCA) algorithm by considering the unbalanced sample numbers in most microarray data of case–control. From the data used by Barth et al. [5] and Censi, et al. [6], we identified 51 differentially expressed genes (DEGs) using the APCA algorithm, in which 42 DEGs are new findings compared with two related works and the existing studies. The enrichment analysis on GO and GAD showed that most identified DEGs are associated with the etiological factors inducing atrial fibrillation. Moreover, we predicted three new signaling pathways. Our analysis and the existing studies supported that the predicted signaling pathways may promote the pmAF progression. The obtained results in this work are worthy to do further experimental studies.
Materials and Methods

Data
The gene expression data used in this work were obtained from the public functional genomics data repository of the National Institute of Health (called Gene Expression Omnibus, GEO). The data with record #GSE2240 consists of samples from 30 patients, in which 10 patients had pmAF, whereas 20 patients had no history of AF and were in SR. The data are related to two Affymetrix platforms U133A and U133B. According to our statistics, 20995 of the 22283 genes in U133A have been annotated and the percentage of annotated genes is 94.2%. Only 14586 of the 22283 genes in U133B have been annotated and the annotated percentage is less than 65%. This may result in wrong interpretation to the final results. Therefore, our study focus on the data in U133A, which is a gene expression data set with 22283 rows (probes) and 30 columns (samples).

APCA algorithm for identifying differentially expressed genes
The existing researches have shown that the PCA-based method on this data set succeed in discriminating patients from controls and in offering a mechanistic view relating AF condition to both cardiac muscle organization and inflammatory processes [6]. However, applying PCA-based method, the total covariance matrices does not effectively remove the unreliable dimensions if one class is represented by its training data much better or much worse than the other class. The asymmetric principal component analysis (APCA) [8] and linear subspace learning-based dimensionality reduction [9] alleviate this problem by asymmetrically weighting the class conditional covariance matrices and by considering the important weak composition. Thus, we design an novel APCA-based method to identify the differentially expressed genes between patients with pmAF and the control group by combining the ideas in two works above [8,9].

Assume that a gene expression dataset is represented by \( X \) with \( m \) rows (probes) and \( l \) columns (samples) and there is \( m \gg l \). The novel APCA – based method consists of four phases. In the phase one, we project \( X \) into a low dimension matrix \( X_S \). The steps are as follows.

1. Construct \( S = X^T X \), where \( T \) denotes the transpose. Obviously, the size of \( S \) is \( lx \).
2. Apply PCA to \( S \) for obtaining the eigenvector matrix \( EIV_S \) with size \( lx \), where one column is one eigenvector.
3. Compute \( EIV_L = XEIV_S \). The \( EIV_L \) is the eigenvector matrix with size \( m \times l \) corresponding to the nonzero eigenvalues of \( XX^T \).
4. Project the \( X \) into \( X_S \) through computing \( X_S = EIV_L^{-1} X \), which is of size \( lx \).

All principal components (PCs) and classification on \( X_S \) will be exactly the same with that on \( X \). In phase two, we construct a new data matrix, shown as below.

1. Suppose that there are \( n \) control samples and \( d \) disease samples in the original data matrix \( X \), and \( n + d = l \). \( X_S \) is divided into two block matrices, that is, \( X_S = [X_{Sn}, \ X_{Sd}] \). Thus, \( X_{Sn} \) is of size \( lx \) and \( X_{Sd} \) \( lx \).
2. Calculate the mean vectors of \( X_{Sn}, X_{Sd} \) and \( X_S \), and \( M_{Sn}, M_{Sd} \) and \( M_S \) whose elements are the mean values over rows and whose sizes are all \( lx \).
3. Centralize the data matrices above by subtracting the means from \( X_{Sn}, X_{Sd} \) and \( X_S \) to yield \( Y_{Sn}, Y_{Sd} \) and \( Y_S \).

(4) Calculate the covariance matrices by 
\[
C_{Sn} = \frac{1}{n} Y_{Sn} Y_{Sn}^T, \\
C_{Sd} = \frac{1}{d} Y_{Sd} Y_{Sd}^T, \text{ and } C_S = \frac{1}{l}[n(M_{Sn}-M_S)(M_{Sn}-M_S)^T+d(M_{Sd}-M_S)(M_{Sd}-M_S)^T] \text{ whose size are all } lx \times lx.
\]
(5) Construct a new matrix \( C = aC_{Sn} + (1-a) C_{Sd} + bC_S \), where the parameter \( b \) is a large value such as 20 and the parameter \( a \) is in the range of 0\(<a\leq1. \) They are determined according to the optimal classification result of patients/control samples based on the first two PCs.

In the third phase, we extract the principal components from \( C \) using the PCA algorithm [9]. The ‘shared variance’ is accounted for by the first PC and the minor PCs (from the second PC onward) keep trace of the relevant among sample difference [6]. In APCA, since the first two PCs could optimally classify the patients/control samples under the selected \( a \) and \( b \), the second PC is used as the discriminant PC, which will be used to identify differentially expressed genes.

The discriminant PC is a vector with dimension of \( 22283 \times 1 \), in which the value in each row represents the score of corresponding gene. In final phase, we identify the DEGs according to the scores of the genes. Those genes, whose scores (in absolute value) are higher than a given threshold (denoted by \( \theta \)), are identified as the DEGs. As we all know, the selection of the threshold is very important. Many biologically relevant DEGs could not be identified if the threshold is too high, while lowering the identification threshold will increase the number of potential DEGs, including many false ones. Based on the reasons above, we select about half of the numerical range of the score \( S \) as the threshold.

Assuming that the score and its maximum value (in absolute value) are respectively indicated by \( S \) and \( |S_{max}| \), the numerical range of the score \( S \) is \( 0 \leq S \leq |S_{max}| \). Thus, the threshold is set as \( \theta = \frac{|S_{max}|}{2} \).

Prediction of pmAF – related pathways

The Affymetrix IDs of all the identified DEGs are entered into the KO-Based Annotation System (KOBASE) [10], which identifies the statistically enriched pathways. An identified pathway is predicted to be associated with pmAF when it satisfies the following criterion: the value of EASE (corrected P-value) for the pathway is less than or equal to 0.05 and meanwhile the number of DEGs involved in the pathway is larger than or equal to 2. This criterion ensures statistical credibility to the predicted results but not a consequence of chance.

Calculation of ROC for the identified DEGs
In order to illustrate the reasonableness of threshold in our method as well as the reliability of the results, we assess the discrimination powers of identified DEG expression levels to classify normal and pmAF samples by calculating their receiver operating characteristic (ROC) curves and the areas under the curve (AUC). In ROC calculation, we respectively define pmAF and normal patients as positive and negative samples. Therefore, the true positive rate indicates how many correct positive results occur among all pmAF samples available during the test. False positive rate, on the other hand, represents how many incorrect positive results occur among all normal samples available during the test.

It is well known that pmAF is a kind of polygenic and multifactorial disease and so its occurrence and progress are associated with the combinational work of multiple genes. Thus, we calculate the ROCs and the AUCs of combinations among 51 identified DEGs. In order to find the combination rules of these DEGs, we analyze the connection relationships among them using...
correlation technique. Using the gene expression values of 51 DEGs across 10 samples in pmAF group of U133A, we calculate the correlation coefficient (CC) between each DEG pair. Under $CC\geq 0.9$ [7], we construct the connection relationship among 51 identified DEGs correspondent to pmAF patients and then combine these DEGs according to the connection relationship for conducting the calculation of ROCs and AUCs. For comparison, we also calculate the ROC and the AUC of each DEG for finding the discrimination powers of these DEGs individually.

Results

The discriminating PC

In U133A data set, there are respectively 22283 probes and 30 samples, which include 20 control samples and 10 disease samples. The independent number of control samples is 19 since the gene expression values of two samples in the control group are completely same. Thus, the total independent sample number is 29. The dimension of data matrix in our experiment are $m = 22283$, $l = 29$, $n = 19$ and $d = 10$.

We let $b$ be an integer of 20 and then uniformly sampled $a$ over the interval (0, 1). Our simulation showed that two kinds of samples can be correctly classified by the first two PCs when taking $a = 0.3$ and $b = 20$ in the APCA algorithm, as shown in Figure 1. Table 1 gave the proportional and cumulative variances represented by the first 10 PCs under $a = 0.3$ and $b = 20$ when our method was applied to the U133A data set.

The results in the Table 1 show that the first PC accounts for 99.61% of total variability in both groups. With the large value of $b$ (here $b = 20$), our algorithm ensures that the first PC is caused by the two class means and it represents the commonality between gene expression profiles on the genome-wide scale. Hence, all minor PCs are caused by the within-class variations of the both classes, which mainly concentrate on the second PC as shown in Table 1. The second PC captures the major difference between the two within-class variations of the two classes. Further, the pmAF patient and control samples are able to be correctly classified using the first two PC and so we select the second PC as the discriminating PC.

The identified DEGs

We obtained each gene’s score using the second PC in Table 1. The maximum value of the score is 11.02. Thus, the threshold of the score $\theta$ is calculated as 5. We identified 51 DEGs (corresponding to the 63 Affymetrix IDs) that have the scores (in absolute value) higher than the threshold. Their symbols, Affymetrix IDs (ID_REF), titles and scores are shown in Table 2, in which the genes DICER1, IGFBP2, LBH and NPR3 marked with italic are the differential expression genes previously reported with italic are the differential expression genes previously reported in the work of [5] on the same data. Also, the genes IGFBP2, IGH@/IGHG1/IGHG2/IGHM/IGHV4-51, LOC100133662/ RPS4Y1, RBP4, SFRP1 and XIST marked with bold are the DEGs previously found on the same data in the work of [6]. Compared with the results of two previous works, 42 new DEGs are identified by our novel method, which fully considers the important weak composition and so can identify some new genes that cannot be found by PCA algorithm and classical supervised approaches.

The predicted pmAF - related signaling pathways

The DEGs in Table 2 are fed into the KOBAS for predicting the pmAF-related signaling pathways. The KOBAS identified three signaling pathways that satisfy the criterion, as shown in Table 3. We inferred these pathways to be associated with development or maintenance of pmAF.

Discrimination powers of identified DEGs

The connection relationships among 51 DEGs correspondent to pmAF patients and the calculation of corresponding ROCs and AUCs are respectively shown in Figure S1, Table S1 and S2. The connection network among 51 DEGs (Figure S1) consisted of two subnetworks, four DEG connection pairs and 29 individual DEGs. In two subnetworks, all the DEGs were found to give an AUC of less than 0.7 or more than 0.3 individually (Table S1), which illustrated single DEG had poor discrimination power. When the DEGs in each subnetwork are combined, we calculated the ROC and AUC of each combinational DEGs and found that two AUCs were elevated to 1 ($P = 0$) (Table S2). In 8 DEGs of four pairs, only DICER1 (No. 8) were found to have an AUC of more than 0.7. When these 8 DEGs combined, the AUC was equal to 1 ($P = 0$).
Table 2. Identified differential expression genes using the APCA algorithm.

| No. | Gene symbol | ID_REF   | Gene Title                                                                 | Score     |
|-----|-------------|----------|-----------------------------------------------------------------------------|-----------|
| 1   | ADIPOQ      | 207175_at| adiponectin, C1Q and collagen domain containing                             | 10.7946   |
| 2   | AMY1A /// AMY1B | 208498_s_at| amylase, alpha 1A (salivary) /// amylase, alpha 1B (salivary) /// amylase, alpha 2A (pancreatic) /// amylase, alpha 2B (pancreatic) | 5.5792    |
| 3   | BMP10       | 208292_at| bone morphogenetic protein 10                                               | -9.7136   |
| 4   | C2 /// CFB  | 202357_s_at| complement component 2 /// complement factor B                              | 7.3188    |
| 5   | C3          | 217767_at| complement component 3                                                      | 7.5830    |
| 6   | CEBPA       | 204039_at| CCAAT/enhancer binding protein (C/EBP), alpha                               | 5.6280    |
| 7   | COL21A1     | 208096_s_at| collagen, type XXI, alpha 1                                                | 7.4379    |
| 8   | Dicer1      | 213229_at| dicer 1, ribonuclease type III                                              | -5.0451   |
| 9   | DIRAS3      | 215506_s_at| DIRAS family, GTP-binding RAS-like 3                                       | 7.1738    |
| 10  | EFEMP1      | 201843_s_at| EGF-containing fibulin-like extracellular matrix protein 1                 | 5.7128    |
| 11  | FABP4       | 203980_at| fatty acid binding protein 4, adipocyte                                     | 11.0171   |
| 12  | FHL2        | 202949_s_at| four and a half LIM domains 2                                               | 5.2915    |
| 13  | GOLGA8A     | 208798_x_at| golgi autoantigen, golgin subfamily a, 8A                                   | 6.2200    |
| 14  | HBA1 /// HBA2 | 204018_x_at| hemoglobin, alpha 1 /// hemoglobin, alpha 2                                | 5.1573    |
|     |             | 217414_x_at|                                                                           | 5.2591    |
|     |             | 211745_x_at|                                                                           | 5.7071    |
|     |             | 214414_x_at|                                                                           | 5.7851    |
|     |             | 209458_x_at|                                                                           | 5.2950    |
|     |             | 211699_x_at|                                                                           | 5.3233    |
| 15  | HBB         | 209116_x_at| hemoglobin, beta                                                            | 5.4556    |
| 16  | HP /// HPF  | 208470_s_at| haptoglobin /// haptoglobin-related protein                                 | 8.6784    |
|     |             | 206697_s_at|                                                                           | 7.9905    |
| 17  | IGF1        | 209541_at| insulin-like growth factor 1 (somatomedin C)                               | 6.1854    |
| 18  | IGF2P2      | 204718_at| insulin-like growth factor binding protein 2, 36 kDa                       | 5.4903    |
| 19  | IGH@ /// IGHAA1 /// IGHG1 /// IGHM /// IGHV4-31 | 217022_s_at| immunoglobulin heavy locus /// immunoglobulin heavy constant alpha 1 /// immunoglobulin heavy variable 4-31 | 6.2667    |
|     |             | 204018_x_at| hemoglobin, alpha 1 /// hemoglobin, alpha 2                                | 5.1573    |
|     |             | 217414_x_at|                                                                           | 5.2591    |
|     |             | 211745_x_at|                                                                           | 5.7071    |
|     |             | 214414_x_at|                                                                           | 5.7851    |
|     |             | 209458_x_at|                                                                           | 5.2950    |
|     |             | 211699_x_at|                                                                           | 5.3233    |
| 20  | IGH@ /// IGHG1 /// IGHG2 /// IGHM /// IGHV4-31 | 211430_s_at| immunoglobulin heavy locus /// immunoglobulin heavy constant gamma 1 /// immunoglobulin heavy constant mu /// immunoglobulin heavy variable 4-31 | 5.4903    |
|     |             | 217022_s_at| hemoglobin, alpha 1 /// hemoglobin, alpha 2                                | 5.1573    |
|     |             | 217414_x_at|                                                                           | 5.2591    |
|     |             | 211745_x_at|                                                                           | 5.7071    |
|     |             | 214414_x_at|                                                                           | 5.7851    |
|     |             | 209458_x_at|                                                                           | 5.2950    |
|     |             | 211699_x_at|                                                                           | 5.3233    |
| 21  | IGL@        | 214677_x_at| immunoglobulin lambda locus                                                | 6.3976    |
|     |             | 209138_x_at|                                                                           | 6.2909    |
| 22  | JUP /// KRT19 | 201650_at| junction plakoglobin /// keratin 19                                        | 7.8226    |
| 23  | LAMB1       | 211651_s_at| laminin, beta 1                                                            | 5.0672    |
|     |             | 201505_at|                                                                           | 6.4921    |
| 24  | LBH         | 221011_s_at| imb bud and heart development homolog                                      | 5.5211    |
of 29 individual DEGs were found to have an AUC of more than 0.7 (Table S1). Among the remaining 19 DEGs, IGFI (NO. 17), MYL2 (NO. 31), PCK1 (NO. 33) and PRKACA (NO. 39) were involved in the pmAF – related PPAR signaling pathways, focal adhesion and dilated cardiomyopathy. When PCK1 was combined with other four DEGs involved in the PPAR pathway, the AUC was more than 0.7 (AUC = 0.926, \(P = 0\)). Similarly, two AUCs for the combinations of DEGs respectively involved in focal adhesion and dilated cardiomyopathy pathways are 0.826 (\(P = 0.004\)) and 0.774 (\(P = 0.017\)). The combination of other 15 individual DEGs was also found to have an AUC of more than 0.7 (AUC = 1, \(P = 0\)).

As have discussed above, different combinations among 51 DEG according to their connection relationships in pmAF samples showed great discrimination power of classifying normal and pmAF samples. This demonstrated that the identified DEGs are reliable and the threshold of identifying DEGs is reasonable.
**Discussion**

The enrichment analysis of identified DEGs

The results for the enrichment analysis of biological process and cellular component on Gene Ontology (GO) and the diseases on Genetic Association Database (GAD) are respectively shown in Table S3, S4 and S5. The existing experimental studies showed that the etiological factors inducing AF mainly include cardiac muscle or organ [1,11], cardiovascular [2], inflammation [12,13], proliferation or differentiation [14], fiber/fibrosis [15,16], external/hormone stimulation [17,18], extracellular region/matrix [19,20] and metabolism [5].

There are respectively 5, 4, and 3 DEGs in the PPAR, focal adhesion and dilated cardiomyopathy pathways (Table 3). The similar results are obtained for the focal adhesion and dilated cardiomyopathy pathways (the data are not given). For instance, in the focal adhesion pathway, the MYL2 and SPP1 interacted in the control (CC = 0.86), but they were not correlated with each other in the pmAF patients (CC = 0.17); although all of the connections among the DEGs in the dilated cardiomyopathy pathway were weak correlation in both pmAF patients and controls, there are great difference between the corresponding CCs in both cases. Thus, we inferred that the alterations of connections among the DEGs in three pathways may be another cause that these signaling pathways promote pmAF.

The study of Censi, et al. [6] illustrated the effectiveness and feasibility of PCA method in finding disease–related biological factors. PCA is undesirable or has drawbacks for the data analysis feasibility of PCA method in finding disease–related biological factors. PCA is undesirable or has drawbacks for the data analysis. Our simulation showed that PCA is undesirable or has drawbacks for the data analysis. The predicted pmAF–related signaling pathways.

| No. | Pathway name | The involved DEG | P-value |
|-----|--------------|------------------|---------|
| 1   | PPAR signaling pathway | ADIPOQ, FABP4, LPL, PLIN, PKC1 | 5.0E-5 |
| 2   | Focal adhesion | IGFI, LAMBI, MYL2, SPP1 | 2.3E-2 |
| 3   | Dilated cardiomyopathy | IGFI, MYL2, PRKACA | 3.3E-2 |

doi:10.1371/journal.pone.0076166.t003

Comparison between the APCA and other related methods

The study of Censi, et al. [6] illustrated the effectiveness and feasibility of PCA method in finding disease–related biological factors. APCA is an improved PCA and both have the same theoretical basis. Therefore we first compare APCA with PCA.

The predicted pmAF–related signaling pathways are probably one of the reasons that these signaling pathways promote the pmAF progression. Further, using gene expression data in U133A, we analyzed the connections among the DEGs involved in each predicted pathway in AF patients and controls respectively [7]. The connection relationships among five DEGs involved in the PPAR signaling pathway are shown in Figure 2. We found that the connections between ADIPOQ and FABP45 and between ADIPOQ and LPL disappear in pmAF patients (Figure 2(A)), while there are strong pairwise connections among ADIPOQ, FABP4, LPL and PLIN in the controls (Figure 2(B)). The ACK1 is isolated in both cases. The similar results are obtained for the focal adhesion and dilated cardiomyopathy pathways (the data are not given). For instance, in the focal adhesion pathway, the MYL2 and SPP1 interacted in the control (CC = 0.86), but they were not correlated with each other in the pmAF patients (CC = 0.17); although all of the connections among the DEGs in the dilated cardiomyopathy pathway were weak correlation in both pmAF patients and controls, there are great difference between the corresponding CCs in both cases. Thus, we inferred that the alterations of connections among the DEGs in three pathways may be another cause that these signaling pathways promote pmAF.
with different numbers of samples in the different classes because PCA uses the number of the samples to weight the class conditional covariance matrix in constructing the total scatter matrix. As such, the class with large number of samples will dominate the results of the principle components of PCA while the information of the class with small number of samples cannot be well shown in its principal components. Now the APCA takes \( a = 0.3 \) and so the larger weight \((1-a) = 0.7\) comparing to \(0.345(10/29)\) of PCA is used for the class of pmAF. Thus, information of the class of pmAF is emphasized in APCA \((0.7 > 0.5)\) while it is deemphasized in PCA \((0.345 < 0.5)\). Furthermore, with \( b = 20\) (it is significantly larger than \( b = 1\) in PCA), APCA forces the largest PC to capture the difference of the class means and hence clearly separates the information about the difference of the class means from the information about the within-class variations into different principal components. PCA with \( b = 1\) makes these two different types of information mixed in various PCs. Thus, the first two PCs of APCA have higher discriminating power of classifying normal and pmAF samples than that of PCA since APCA considers the unbalanced sample numbers.

Numerous feature selection methods have been applied to the identification of DEGs on microarray, including Fold change, Welch t-statistic, SAM (Significance Analysis of Microarray), etc. [27]. The feature selection methods separately identify each DEG that has significant difference in statistics and the number of identified DEGs is usually very large, while APCA identify DEGs whose expressions are correlated. Since the AF signature is activated by a general modulation of the whole genome but a single gene, APCA is able to better characterize different pathophysiological aspects of AF. Typically, the number of samples is limited by the availability of sufficient patients or cost and the noise is inevitable in a microarray study. The number of samples and noise are significant challenge to any feature selection approaches [27], while APCA is more robust to both factors [28]. For a microarray data with unbalanced samples, APCA is able to allocate larger weight to the group with fewer sample number for reducing the influence of imbalance on the final results. Therefore APCA can produce more reliable results than other methods that do not consider the problem of unbalanced sample number when processing U133A dataset, which is a typical microarray data with unbalanced samples.

**Comparing with the existing results**

By PCA, Censi, et al. identified 50 pmAF-related DEGs from the same data set [6]. APCA and PCA’s mechanisms of weighting two classes of samples (pmAF and control) are very different so that the scores of same a gene generated by APCA and PCA are very different. Therefore, APCA and PCA identify different DEG lists that have very low overlap. This is the main reason why only 6 genes are same between two DEG lists identified by our and Censi, et al.’s methods.

Our enrichment analysis about biological process and cellular component on GO for 50 DEGs also shows the majority of them (27 DEGs, while ours is 37 DEGs) are individually related to the etiological factors inducing AF. Using 50 DEGs extracted by Censi, et al., we do not find any a gene is included in the statistically enriched GAD terms of disease on GAD (we have 22 DEGs), and only one statistically enriched pathway named focal adhesion is found on KOBAS, in which genes JUN, PIK3R1, TNC and THBS4 are involved. This illustrates that the correlation in biological functions among our 51 DEGs is higher than that of

![Figure 2. The connection relationships among 5 DEGs in the PPAR signaling pathway.](https://example.com/figure2)

![Figure 3. The first 10 PCs extracted by APCA and PCA](https://example.com/figure3)
50 DEGs. Therefore, there are more genes and combinational works of multiple genes in our 51 DEGs to be associated with occurrence and progress of pmAF. APCA is a more appropriate method to microarray data that have unbalanced samples.

Finally, it is worthy explaining that we do not analyze the U133B data set because too many genes were not annotated on this chip, which may result in wrong interpretation to the final results. The pathophysiology of pmAF is extremely complex. In our future work, we shall validate the suggested pmAF-related DEGs in experiments and integrate multiple types of data (such as gene sequence, RNA and miRNA expression profiles, protein-protein interactions) to build functional networks promoting pmAF for more comprehensive understanding of pmAF pathophysiology.

Conclusion

This work proposes a novel method to identify the DEGs from microarray data with unbalanced sample numbers. 51 DEGs associated with pmAF are identified, in which 42 DEGs are different from the existing related results. The PPAR, focal adhesions and dilated cardiomyopathy signaling pathways are predicted to be associated with pmAF based on all of the identified DEGs. This work provides some new insights into biological features of pmAF and has also the potentially important implications for improved understanding of the molecular mechanisms of pmAF.

Supporting Information

Figure S1 The connection network among 51 identified DEGs. The No. of each DEG is same with that in Table 2.

Table S1 The AUCs of 51 DEGs individually.

Table S2 The AUCs of combination among multiple genes.

Table S3 The statistically enriched GO terms of biological processes.

Table S4 The statistically enriched GO terms of cellular component.

Author Contributions

Conceived and designed the experiments: FO NR XDJ LXY XC. Performed the experiments: FO MYQ WF. Analyzed the data: NR XDJ LXY XC. Contributed reagents/materials/analysis tools: FO NR XDJ. Wrote the paper: FO NR XDJ.

References

1. Nattel S (2002) New ideas about atrial fibrillation 50 years on. Nature 415: 219–226.
2. Schotten U, Asuma J, Stellbrink C, Sahasruva I, Vogel M, et al. (2001) Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation 103: 691–698.
3. Kim YH, Lee JH, Lim DS, Shin WJ, Ro YM, et al. (2003) Gene expression profiling of oxidative stress on atrial fibrillation in humans. Experimental and Molecular Medicine 35: 336–349.
4. Ohki-Kaneda R, Ohashi J, Yamamoto K, Ueno S, Ota J, et al. (2004) Cardiac function-related gene expression profiles in human atrial myocytes. Biochemical and Biophysical Research Communications 320: 1328–1336.
5. Barth AS, Merk S, Arnoldi E, Zweramm L, Kloos P, et al. (2005) Reprogramming of the human atrial transcriptome in permanent atrial fibrillation - Expression of a ventricular-like genomic signature. Circulation Research 96: 1022–1029.
6. Cesni F, Calacagnini G, Bartolini P, Giulianni A (2010) A Systems Biology Strategy on Differential Gene Expression Data Discloses Some Biological Features of Atrial Fibrillation. Plos One 5.
7. Cesni F, Giulianni A, Bartolini P, Calacagnini G (2011) A Multiscale Graph Theoretical Approach to Gene Regulation Networks: A Case Study in Atrial Fibrillation. IEEE Transactions on Biomedical Engineering 58.
8. Jiang X (2009) Asymmetric Principal Component and Discriminant Analyses for Pattern Classification. IEEE TRANSACTIONS ON PATTERN ANALYSIS AND MACHINE INTELLIGENCE 31: 931–937.
9. Jiang X (2011) Linear Subspace Learning-Based Dimensionality Reduction. Ieee Signal Processing Magazine 28: 16–26.
10. Wei J, Mao X, Cai T, Luo J, Wei L (2006) KOBAS server: a web-based platform for automated annotation and pathway identification. Nucleic Acids Research 34: W720-W724.
11. Asuma J, Wulfso M, van Eys G, Koide M, Ramackers F, et al. (1997) Differferentiation of atrial cardiomyocytes as a result of chronic atrial fibrillation. The American journal of pathology 151: 985–997.
12. Korantzopoulos P, Kepliti T, Sioga K, Goudevenos J (2003) Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Medical science monitor : international medical journal of experimental and clinical research 9: RA225–229.
13. Sata N, Hameda N, Horinouchi T, Amatani S, Yamashita T, et al. (2006) C-reactive protein and atrial fibrillation - Is inflammation a consequence or a cause of atrial fibrillation? Japanese Heart Journal 45: 441–445.
14. Burstein B, Nattel S (2008) Atrial fibrisc: Mechanisms and clinical relevance in atrial fibrillation. Journal of the American College of Cardiology 51: 802–809.
15. Shimano M, Tsuji T, Imura S, Kimura K, Uchikawa T, et al. (2008) Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 5: 451–459.
16. Evett TH, Olga JF (2007) Atrial fibrillation and the mechanisms of atrial fibrillation. Heart Rhythm 4: S24-S27.
17. Alliesse M, Kirchof C, Schiffer GJ, Chorro F, Brugada J (1991) Regional control of atrial fibrillation by rapid pacing in conscious dogs. Circulation 84: 1697–1697.
18. Kneller J, Zou RQ, Vignod EJ, Wang ZG, Leon LJ, et al. (2002) Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. Circulation Research 90: E73-E27.
19. Groote A, Stanek F, Rocken C, Arndt M, Geller JC, et al. (2000) Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. Journal of the American College of Cardiology 35: 1669–1677.
20. Xu J, Cui GG, Esmailian F, Plunkett M, Marrilli D, et al. (2004) Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109: 363–368.
21. Chinetti G, Grigolo S, Antonucci M, Torra IP, Debire P, et al. (1999) Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. The Journal of biological chemistry 273: 25375–25380.
22. Barbier O, Torra IP, Dugay Y, Blanquart G, Frucht JC, et al. (2002) Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arteriosclerosis Thrombosis and Vascular Biology 22: 717–726.
23. Fraley S, Feng Y, Kruhnarmuthy R, Kim D-H, Caleo AP, et al. (2010) A distinctive role for focal adhesion proteins in three-dimensional cell motility. Nature Cell Biology 12.
24. Samarat AM (2005) Costameres, focal adhesions, and cardiomyocyte mechanotransduction. American Journal of Physiology-Heart and Circulatory Physiology 289: H2291–H2301.
25. Goudis CA, Kallergis EM, Vardas PE (2012) Extracellular matrix alterations in the atria: insights into the mechanisms and perpetuation of atrial fibrillation. Europace 14: 623–630.
26. Olson TM, Michels VV, Balles JD, Reyna SP, Karst ML, et al. (2005) Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. Jama- Journal of the American Medical Association 293: 447–454.
27. Jeffery JB, Huggins DJ and Calhane AG. (2006) Comparison and evaluation of methods for generating differentially expressed gene lists from microarray data. BMC Bioinformatics 7:359.
28. Wall ME, Rechte and Aroha LM. (2003) Singular value decomposition and principal component analysis. In A Practical Approach to Microarray Data, Klaver Norwell LA-UR-02-4001–91-109.